Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders offender sample from Austria". Every profession has their own standards of care, but the following treatments are a few standards of care that are used as a set of guidelines for any and all professions. Two types of treatment commonly used for the treatment of sexual offenders include psychological and biomedical treatment. The psychological treatment includes different therapies that were made to treat sexual offenders. Both of the different treatments are based on different psychological and psychiatric theories that target the initial paraphilia sexual offending. The psychological and psychiatric care are provided in different forms. The different forms can be